Download Files:

MF498

$62$504

Products Details

Product Description

– MF498 is a selective and orally active E prostanoid Receptor 4 (EP4) antagonist with a Ki value of 0.7 nM. MF498 can be used in the research of inflammation, such as rheumatoid and osteoarthritis[1][2].

Web ID

– HY-10794

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– Metabolism-protein/nucleotide metabolism

Molecular Formula

– C32H33N3O7S

References

– [1]Clark P, et al. MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. J Pharmacol Exp Ther. 2008 May;325(2):425-434.|[2]Xu H, et al. The Prostaglandin E2 Receptor EP4 Promotes Vascular Neointimal Hyperplasia through Translational Control of Tenascin C via the cAPM/PKA/mTORC1/rpS6 Pathway. Cells. 2022 Aug 31;11(17):2720.

CAS Number

– 915191-42-3

Molecular Weight

– 603.69

Compound Purity

– 99.26

SMILES

– O=C1N(C2=C(C)C=C(CS(NC(CC3=CC=CC=C3OC)=O)(=O)=O)C=C2)CC4=C(OCC)C5=NC=CC=C5C(OCC)=C41

Clinical Information

– No Development Reported

Research Area

– Cancer; Metabolic Disease; Inflammation/Immunology

Solubility

– DMSO : ≥ 31 mg/mL

Target

– Prostaglandin Receptor

Isoform

– EP

Pathway

– GPCR/G Protein

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.